November 25th, 2019 | 05:54 CET
MPH Health Care investment HAEMATO with growth in Q3 - shares before turnaround?
HAEMATO AG, a provider of special pharmaceuticals and a subsidiary of MPH Health Care, which is also listed on the stock exchange, returned to growth in the third quarter of 2019. The company is also continuing to optimize its business processes and approve new products in order to broaden its portfolio. This means that the stocks could also face a turnaround. Analysts also see significant price potential.
time to read: 1 minutes
|
Author:
Mario Hose
ISIN:
DE0006190705 , DE000A0L1H32 , DE000A0STSQ8
Table of contents:
Author
Mario Hose
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Tag cloud
Shares cloud
Solid healthcare market environment
After HAEMATO was able to shine with solid growth and high dividends in the past years, the streamlining of the portfolio with low-margin products and the expiration of patents for some high-revenue original preparations led to a decline in sales in 2018 and especially in the first half of 2019. This phase now seems to have been overcome. The fundamentally solid outlook for the healthcare market has not changed.
Specialization in drugs
As one of the leading suppliers of special pharmaceuticals, the HAEMATO Group benefits from competition in the first healthcare market. The specialisation in drugs for the treatment of chronic diseases and for individual therapies is expected to remain positive in the future due to demographic developments.
Analysts see clear potential
The analysts of First Berlin and GBC Research see clear price potential. Both recommend buying the HAEMATO stocks. The price targets are EUR 4.80 (First Berlin) and EUR 6 (GBC). GBC sees the conclusion of the framework agreement between the GKV (Central Association of Health Insurance Funds) and the German Pharmacy Association as a good basis for continued high demand for HAEMATO products.
In addition, new sources of revenue are to be tapped. In addition to the parallel imports business segment, the area of pharmaceutical, medical and medical technology products for aesthetic treatments and cosmetics is to be addressed in future. The first hyaluronic acid-based products, which are distributed via the pharmacy network, were introduced in Germany in 2018. The listed investments of MPH also include M1 Kliniken AG and CR Real Estate AG.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
